

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Jill Giles Komar, et. al. 26 April 2007  
Serial No. : 09/920,267 Art Unit: 1644  
Filed : 01 August 2001 Examiner: Maher M. Haddad  
For : ANTI-DUAL INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS  
AND USES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: J. ORIHARA, 'SENSITIZING CAPACITY, CROSS- REACTIVITY AND ANTIGENIC DETERMINANTS OF BISPHENOL A', THE JOURNAL OF STOMATOLOGICAL SOCIETY, VOL 59, NO. 2, JUNE 1992, PP. 439-455, ENGLISH ABSTRACT

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN0249/KJD.

Respectfully submitted,

/Kenneth J. Dow/  
Reg. No. 32,890  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(610) 651-7422  
DATED: 26 April 2007

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	09/920,267
<b>Filing Date</b>	August 1, 2001
<b>First Named Inventor</b>	Jill Giles-Komar
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	Maher M. Haddad
<b>Attorney Docket Number</b>	CEN0249

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,753,230	A	Brooks, et. al.	5-19-1998	
		5,877,397	A	Lonberg, et. al.	3-02-1999	
		6,342,221	B1	Thorpe, et. al.	6-29-2002	
		6,632,927	B1	Adair et. al.	10-14-2003	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		EP	0 260 829		Westinghouse Electric Corporation	3-23-1988		
		EP	0 834 557		Takeada Chemical Industries, LTD	4-08-1998		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		PANKA et. al., VARIABLE REGION FRAMEWORK DIFFERENCES RESULT IN DECREASED OR INCREASED AFFINITY OF VARIANT ANTI-DIGOXIN ANTIBODIES, Proc. Natl. Acad. Sci. U.S.A. 85 (9); 3080-3084, 1988	
		AMIT, et. al., THREE-DIMENSIONAL STRUCTURE OF AN ANTIGEN-ANTIBODY COMPLEX AT 2.8 A RESOLUTION. Science. 233 (4765); 747-753, 1986	
		WAYNER et. al., INTEGRINS ALPHA V BETA 3 AND ALPHA V BETA 5 CONTRIBUTE TO CELL ATTACHMENT TO VITRONECTIN BUT DIFFERENTIALLY DISTRIBUTE ON THE CELL SURFACE. J. CELL BIOL. MAY 1991; 113(4); 919-29	
		J. ORIHARA, 'SENSITIZING CAPACITY, CROSS- REACTIVITY AND ANTIGENIC DETERMINANTS OF BISPHENOL A', THE JOURNAL OF STOMATOLOGICAL SOCIETY, VOL 59, NO. 2, JUNE 1992, PP. 439-455, ENGLISH ABSTRACT	
		M. CASTILLO ET. AL., "ANALYSIS OF INDUSTRIAL EFFLUENTS TO DETERMINE ENDOCRINE-DISRUPTING CHEMICALS", TRENDS IN ANALYTICAL CHEMISTRY VOL. 16, NO. 10, NOV. 12, 1997, PP 574-583	
		J. GASCON ET. AL. "DETECTION OF ENDOCRINE-DISRUPTING PESTICIDES BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA); APPLICATION TO ATRAZINE" TRENDS IN ANALYTICAL CHEMISTRY, VOL. 16, NO. 10, 1997, PP. 554-562	
		FRIENDLANDER ET. AL, PROC NATL ACAD SCI, 1996, PP 9764-9769, VOL. 93	
		CHEMICON INTERNATIONAL CATALOG NO. MAB1953Z, P.1, JAN 27, 2006	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.